Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin DE000BAY0017
Ticker BAYN.DE
Company BAYER
Currency
Price
Aware Investor Index (AII) 0.8430
Recommendation BUY
P/E 24.61
ROE 11.92 %
Capitalization 64,292,226,014 $
Dividend Yield 4.41 %
P/S 1.58
AII Position 258
P/E Position 339
ROE Position 299
Capitalization Position 130
Dividend Yield Position 122
Sales 35,015,000,000 €
10-Year Average Earnings 2,250,400,000 €
Shares Outstanding 872,107,808
Equity 18,875,000,000 €
Dividend per Share 2.8 €
Industry Pharmaceutical
Country Germany
BAYER Investor Relations Web Site http://www.investor.bayer.com/en/







Sales:

YEAR MONTH AMOUNT
2017 12 35,015,000,000.00 €
2016 12 34,943,000,000.00 €
2015 12 46,324,000,000.00 €
2014 12 42,239,000,000.00 €
2013 12 40,157,000,000.00 €
2012 12 39,760,000,000.00 €
2011 12 36,528,000,000.00 €
2010 12 35,088,000,000.00 €
2009 12 31,168,000,000.00 €
2008 12 32,918,000,000.00 €

Earnings:

YEAR MONTH AMOUNT
2017 12 2,900,000,000.00 €
2016 12 2,233,000,000.00 €
2015 12 4,110,000,000.00 €
2014 12 3,426,000,000.00 €
2013 12 3,189,000,000.00 €
2012 12 889,000,000.00 €
2011 12 1,125,000,000.00 €
2010 12 1,245,000,000.00 €
2009 12 2,226,000,000.00 €
2008 12 1,161,000,000.00 €

Equity:

YEAR MONTH AMOUNT
2017 12 18,875,000,000.00 €
2016 12 16,565,000,000.00 €
2015 12 24,265,000,000.00 €
2014 12 20,106,000,000.00 €
2013 12 13,888,000,000.00 €
2012 12 14,363,000,000.00 €
2011 12 13,888,000,000.00 €

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 872,107,808
2016 12 832,502,808
2015 12 826,947,808
2014 12 826,947,808
2013 12 826,947,808
2012 12 826,947,808
2011 12 826,950,000

 












Bloomberg News for BAYER:



Google News for BAYER:

The Pharma Letter - 3 days ago
Bayer presents positive third quarter financial results
Germany's Bayer (BAYN: DE) has provided an upbeat third quarter financial results statement, showing sales of pharmaceuticals rose by 4.8% ...
Southgate Observer - 1 day ago
Investor Update: Stock Lower -17.60% Over the Last Month: Bayer ...
After a recent check, we have noted that Bayer AG (BAYN.DE) shares have dropped -17.60% lower over the past 4-weeks. Checking on ...
The Pharma Letter - 2 days ago
Stivarga to be tested as therapy for glioblastoma
Bayer's (BAYN: DE) Stivarga (regorafenib) will be subject to a new trial run by The Global Coalition for Adaptive Research (GCAR), called GBM ...
The Pharma Letter - 24 Oct 2018
Orion and Bayer's darolutamide meets Phase III primary endpoint in ...
Finnish drugmaker Orion Corp (Nasdaq OMX: ORNAV) and Germany's Bayer (BAYN: DE) have completed the Phase III clinical trial (ARAMIS) ...
The Pharma Letter - 21 Oct 2018
Loxo and Bayer present positive biomarker-based data for ...
East Coast, USA-based Loxo Oncology (Nasdaq: LOXO) and Germany's Bayer (BAYN: DE) have announced clinical data for their ...
The Pharma Letter - 4 days ago
Keytruda claims 14th approval
... (HCC) who have been previously treated with sorafenib, a drug from Germany's Bayer (BAYN: DE) that is marketed under the name Nexavar.
The Pharma Letter - 8 Nov 2018
NICE recommends Lenvima in new setting
... an overall survival treatment effect that was non-inferior to the current standard of care, which is Bayer's (BAYN: DE) Nexavar (sorafenib).
The Pharma Letter - 26 Oct 2018
Regeneron data update on Eylea overshadowed by CRL
Shares in Regeneron closed 3% down on Thursday, and they were also down for its partner Bayer (BAYN: DE). Only last month, the FDA ...
The Pharma Letter - 6 Nov 2018
Eylea leads the way to strong third quarter for Regeneron
The firm's strong performance was driven by a 7% rise in US sales of Eylea (aflibercept), partnered with Bayer (BAYN: DE), to $1 billion, and an ...
The Pharma Letter - 29 Oct 2018
Latest data on brolucizumab superiority versus aflibercept
Brolucizumab met its primary endpoint of non-inferiority versus aflibercept – Bayer's (BAYN: DE) Eylea - in best corrected visual acuity (BCVA) ...


Back